Literature DB >> 19871511

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES.

C M Macleod1, R G Hodges, M Heidelberger, W G Bernhard.   

Abstract

1. Immunization of man with 0.03 to 0.06 mg. of each of the capsular polysaccharides of pneumococcus types I, II, V, and VII, given in a single subcutaneous injection, has been shown to be effective in preventing pneumonia caused by these types but not that due to heterologous types. 2. Immunity appears within a period of 2 weeks following injection of the polysaccharides. Its duration was not determined, although 6 months can be set as a minimum. 3. Immunization of alternate subjects in the population reduced greatly the incidence of pneumonia in the non-immunized. 4. The carrier rate for pneumococcus types I, II, V, and VII was lowered significantly in the immunized group as compared with the controls. It is suggested that an over-all reduction in the incidence of carriers was responsible for the lowered rates for pneumococcal pneumonia in the non-immunized group.

Entities:  

Year:  1945        PMID: 19871511      PMCID: PMC2135567     

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  The Precipitation of Bacterial Polysaccharides with Calcium Phosphate : Pneumococcus.

Authors:  L D Felton; G Kauffmann; H J Stahl
Journal:  J Bacteriol       Date:  1935-02       Impact factor: 3.490

2.  QUANTITATIVE MICRO-ESTIMATION OF ANTIBODIES IN THE SERA OF MAN AND OTHER ANIMALS.

Authors:  M Heidelberger; C F Macpherson
Journal:  Science       Date:  1943-04-30       Impact factor: 47.728

3.  A SIMPLE METHOD FOR PREPARING ANTIGENIC SUBSTANCES FROM THE TYPHOID BACILLUS.

Authors:  J W Palmer
Journal:  Science       Date:  1940-08-16       Impact factor: 47.728

4.  A Study of a Type I Pneumococcus Epidemic at the State Hospital at Worcester, Mass.

Authors:  W G Smillie; G H Warnock; H J White
Journal:  Am J Public Health Nations Health       Date:  1938-03

5.  QUANTITATIVE STUDIES ON THE PRECIPITIN REACTION : THE DETERMINATION OF SMALL AMOUNTS OF A SPECIFIC POLYSACCHARIDE.

Authors:  M Heidelberger; F E Kendall
Journal:  J Exp Med       Date:  1932-03-31       Impact factor: 14.307

6.  CUTANEOUS REACTIONS IN PNEUMONIA. THE DEVELOPMENT OF ANTIBODIES FOLLOWING THE INTRADERMAL INJECTION OF TYPE-SPECIFIC POLYSACCHARIDE.

Authors:  T Francis; W S Tillett
Journal:  J Exp Med       Date:  1930-09-30       Impact factor: 14.307

7.  RESULTS OF PROPHYLACTIC VACCINATION AGAINST PNEUMONIA AT CAMP WHEELER.

Authors:  R L Cecil; H F Vaughan
Journal:  J Exp Med       Date:  1919-05-01       Impact factor: 14.307

8.  FURTHER STUDIES ON THE EPIDEMIOLOGY OF LOBAR PNEUMONIA.

Authors:  E G Stillman
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

  8 in total
  80 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

3.  Pneumococcal antigens and serum antibody responses in experimentally induced sinusitis.

Authors:  K M Westrin; A Freijd; P Stierna
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

Review 4.  Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Authors:  Richard Malley; Porter W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-02       Impact factor: 11.205

5.  Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.

Authors:  Daniel M Musher; Maria B Rodriguez-Barradas
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

6.  Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L.

Authors:  Y i Hwang; M H Nahm; D E Briles; D Thomas; J M Purkerson
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

7.  Specific intracellular adhesion molecule-grabbing nonintegrin R1 is not involved in the murine antibody response to pneumococcal polysaccharides.

Authors:  Leen Moens; Axel Jeurissen; Greet Wuyts; Padraic G Fallon; Boon Louis; Jan L Ceuppens; Xavier Bossuyt
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

8.  Biochemical activities of Streptococcus pneumoniae serotype 2 capsular glycosyltransferases and significance of suppressor mutations affecting the initiating glycosyltransferase Cps2E.

Authors:  David B A James; Kanupriya Gupta; Jocelyn R Hauser; Janet Yother
Journal:  J Bacteriol       Date:  2013-10-04       Impact factor: 3.490

9.  Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization.

Authors:  Tera L McCool; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae.

Authors:  D E Briles; M Nahm; K Schroer; J Davie; P Baker; J Kearney; R Barletta
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.